It is intriguing whether the anti-inflammatory effects of IL-10 in this setting might be explained by its ability to induce mediators such as LILRA3 [31, 32] and failure to respond to IFNβ treatment in a subset of patients with MS might in part be due to deficiencies in secondary messengers such as LILRA3. The gene discussed is IL10; the disease is myeloid sarcoma.